RxDoctor Payments Data

Paul Tchao, MD

Internal Medicine · Deer Park, NYNPI 1346286796

Payments from drug & device makers

$821in general payments, 2019–2025

Across 18 payments — averaging $45.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$244
  • Edwards Lifesciences$141
  • Novo Nordisk$116
  • Lilly USA, LLC$104
  • Exact Sciences$74
  • Genentech USA, Inc.$61
  • plus $80 from 4 others

What the payments were for

  • Food & beverage$821100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$821 in reported general payments places this provider in the 70th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$62,311
Medicare patients
97
Services billed
809

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide18$24,019
MounjaroTirzepatide15$15,170
Metoprolol Succinate123$1,734
Bisoprolol-HydrochlorothiazideBisoprolol/Hydrochlorothiazide72$1,024
Rosuvastatin Calcium92$971
Ursodiol13$969
SynthroidLevothyroxine Sodium20$868
Levothyroxine Sodium95$798
Metformin Hcl118$646
Ezetimibe27$620
Amlodipine Besylate100$503
Atorvastatin Calcium82$447
Celecoxib17$416
Esomeprazole Magnesium19$383
Topiramate26$348

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$116$24,01918 claims
Lilly USA, LLCMounjaro$104$15,17015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Deer Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →